Subject: Renal cell cancer | Molecular Medicine | Integrin | Research | CD98 | Cancer Research | Oncology
Background Overexpression of CD98hc (SLC3A2) occurs in a variety of cancers and is suspected to contribute to tumor growth. CD98, a heterodimeric transmembrane protein, physically associates with certain integrin β subunit cytoplasmic domains via its heavy chain, CD98hc... View more
1. Rini BI, et al: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378(9807):1931-1939.
2. Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ: Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Clin Genitourin Cancer 2013, 11:45-50.
3. Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al: Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 2012, 107:1665-1671.